Inhibition of secretory phospholipase A 2 in patients with acute coronary syndromes: Rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial

Cardiovascular Drugs and Therapy

Volumn 26, Issue 1, 2012, Pages 71-75

  Nicholls, Stephen J ^a   Cavender, Matthew A ^a   Kastelein, John J P ^b   Schwartz, Gregory ^c   Waters, David D ^d   Rosenson, Robert S ^e   Bash, Dianna ^a   Hislop, Colin ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Anthera Pharmaceuticals   (United States)

Author keywords

Acute coronary syndromes; Inflammation; Risk factors; Secretory phospholipase

Indexed keywords

ATORVASTATIN; PLACEBO; PRAVASTATIN; SECRETORY PHOSPHOLIPASE A2; STATIN; VARESPLADIB; VARESPLADIB METHYL;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT TOOL; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HEART INFARCTION; HEART PROTECTION; HOSPITALIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROKE; TREATMENT DURATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ACETATES; ACUTE CORONARY SYNDROME; DOUBLE-BLIND METHOD; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INFLAMMATION; PHOSPHOLIPASES A2, SECRETORY; PYRROLES;

EID: 84857792744     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6358-9     Document Type: Article

References (24)

1. GW Stone A Maehara AJ Lansky, et al. 2011 A prospective natural-history study of coronary atherosclerosis N Engl J Med 364 226 35 21247313 10.1056/NEJMoa1002358 1:CAS:528:DC%2BC3MXhtVGhtLw%3D
2. A Thompson P Gao L Orfei, et al. 2010 Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies Lancet 375 1536 44 20435228 10.1016/S0140-6736(10)60319-4 1:CAS:528:DC%2BC3cXlsVOnt78%3D
3. Z Mallat PG Steg J Benessiano, et al. 2005 Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes J Am Coll Cardiol 46 1249 57 16198839 10.1016/j.jacc.2005.06.056 1:CAS:528:DC%2BD2MXhtlarsr7F (Pubitemid 41615545)
4. R Nijmeijer WK Lagrand A Baidoshvili, et al. 2002 Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans Cardiovasc Res 53 138 46 11744022 10.1016/S0008-6363(01)00480-1 1:CAS:528:DC%2BD3MXptVahtro%3D (Pubitemid 34020774)
5. MJ Caslake CJ Packard 2003 Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease Curr Op Lipidol 14 347 52 10.1097/00041433-200308000-00002 1:CAS:528: DC%2BD3sXlsVKnsrY%3D (Pubitemid 36951899)
6. H Arakawa JY Qian D Baatar, et al. 2005 Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic rabbits Circulation 111 3302 9 15956136 10.1161/CIRCULATIONAHA.104.476242 1:CAS:528:DC%2BD2MXltVKmtro%3D (Pubitemid 40875004)
7. PW Serruys HM Garcia-Garcia P Buszman, et al. 2008 Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 1172 82 18765397 10.1161/CIRCULATIONAHA. 108.771899 1:CAS:528:DC%2BD1cXhtVOiurjK
8. D De Keyzer SA Karabina W Wei, et al. 2009 Increased PAFAH and oxidized lipids are associated with inflammation and atherosclerosis in hypercholesterolemic pigs Arterioscl Thromb Vasc Biol 29 2041 6 19797705 10.1161/ATVBAHA.109.196592
9. ML O'Donoghue E Braunwald HD White, et al. 2011 Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome Am Heart J 162 613 9 e1 21982651 10.1016/j.ahj.2011.07.018
10. H White C Held R Stewart, et al. 2010 Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease Am Heart J 160 655 61 20934559 10.1016/j.ahj.2010.07.006 1:CAS:528:DC%2BC3cXht1Kqtr7F
11. RH Schaloske EA Dennis 2006 The phospholipase A2 superfamily and its group numbering system Biochim Biophys Acta 1761 1246 59 16973413 1:CAS:528:DC%2BD28Xht1CisLvM (Pubitemid 44755364)
12. M Murakami S Masuda S Shimbara, et al. 2003 Cellular arachidonate- releasing function of novel classes of secretory phospholipase A2s (groups III and XII) J Biol Chem 278 10657 67 12522102 10.1074/jbc.M211325200 1:CAS:528:DC%2BD3sXitVCqsL4%3D (Pubitemid 36800335)
13. TJ Nevalainen MM Haapamaki JM Gronroos 2000 Roles of secretory phospholipases A(2) in inflammatory diseases and trauma Biochim Biophys Acta 1488 83 90 11080679 1:CAS:528:DC%2BD3cXotlGitr8%3D
14. JJ Seilhamer W Pruzanski P Vadas, et al. 1989 Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid J Biol Chem 264 5335 8 2925608 1:CAS:528:DyaK3cXhslaktg%3D%3D (Pubitemid 19097981)
15. B Ivandic LW Castellani XP Wang, et al. 1999 Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 Arterioscl Thromb Vasc Biol 19 1284 90 10323781 10.1161/01.ATV.19.5.1284 1:CAS:528:DyaK1MXkvFaktb4%3D (Pubitemid 29227649)
16. S Gora S Maouche R Atout, et al. 2010 Phospholipolyzed LDL induces an inflammatory response in endothelial cells through endoplasmic reticulum stress signaling FASEB 24 3284 97 10.1096/fj.09-146852 1:CAS:528:DC%2BC3cXhtFGgtrbL
17. SA Karabina I Brocheriou G Le Naour, et al. 2006 Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB 20 2547 9 10.1096/fj.06-6018fje 1:CAS:528:DC%2BD28Xht1yntr3M (Pubitemid 44953776)
18. ME Paradis MO Hogue JF Mauger, et al. 2006 Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL Int J Obes 30 1615 22 10.1038/sj.ijo.0803315 1:CAS:528:DC%2BD28XhtFekt7nO (Pubitemid 44657835)
19. E Hurt-Camejo S Andersen R Standal, et al. 1997 Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins Arterioscl Thromb Vasc Biol 17 300 9 9081685 10.1161/01.ATV.17.2.300 1:CAS:528:DyaK2sXhvFCjsr0%3D (Pubitemid 27098188)
20. PY Liu YH Li WC Tsai, et al. 2003 Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur Heart J 24 1824 32 14563341 10.1016/j.ehj.2003.07.003 1:CAS:528:DC%2BD3sXotVCit74%3D (Pubitemid 37280248)
21. Z Shaposhnik X Wang J Trias H Fraser AJ Lusis 2009 The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) J Lipid Res 50 623 9 19029066 10.1194/jlr.M800361- JLR200 1:CAS:528:DC%2BD1MXks1Wisb8%3D
22. V Dzavik S Lavi K Thorpe, et al. 2010 The sPLA2 inhibition to decrease enzyme release after percutaneous coronary intervention (SPIDER-PCI) trial Circulation 122 2411 8 21098449 10.1161/CIRCULATIONAHA.110.950733 1:CAS:528:DC%2BC3cXhsFaqs7vP
23. RS Rosenson C Hislop D McConnell, et al. 2009 Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 649 58 19231633 10.1016/S0140-6736(09)60403-7 1:CAS:528: DC%2BD1MXitFyrsLc%3D
24. RS Rosenson C Hislop M Elliott Y Stasiv M Goulder D Waters 2010 Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients J Am Coll Cardiol 56 1079 88 20863951 10.1016/j.jacc.2010.06.015 1:CAS:528:DC%2BC3cXhtlymtrfO